Pharmaceuticals(42)

  • PROMISE search engine for PTMs and Neoantigens (No. T4-2090)

    Many newly developed anti-cancer treatments rely on identifying cancer unique signatures that can be used to harness the immune system against the tumor. ... Read more
    Senior Scientist Yifat Merbl

    Yifat Merbl

    Faculty of Biology

    6011
  • A Novel Target for Treating and Diagnosing Refractory or Relapsing Multiple Myeloma (No. T4-2075)

    Multiple myeloma (MM) is an incurable malignancy, and despite novel anti-myeloma drugs that increased survival, up to 30% of patients develop primary resistance, and many patients experience early relapse. ... Read more
    Associate Professor Ido Amit

    Ido Amit

    Faculty of Biology

    6019
  • Methods of diagnosing cancer and predicting responsiveness to therapy (No. T4-2066)

    Immunotherapy was proven very efficient for some patients revolutionizing cancer treatment; however, many patients fail to respond to the treatment. It is currently unknown which patients will respond to immunotherapy. ... Read more
    Senior Scientist Ravid Straussman

    Ravid Straussman

    Faculty of Biology

    6018
  • Increasing Efficiency of Therapeutic A-to-I RNA Editing (No. T4-2028)

    Single-point mutations can give rise to a wide spectrum of genetic diseases. Recent therapeutic approaches aim at editing the mutated mRNA, providing a safe, reversible and tunable treatment. ... Read more
    Senior Scientist Schraga Schwartz

    Schraga Schwartz

    Faculty of Biochemistry

    6016
  • Ultra tight ACE2 binder for prevention of SARS-Cov-2 infection (No. T4-2024)

    combat against COVID-19 is still ongoing worldwide. ... Read more
    Full Professor Gideon Schreiber

    Gideon Schreiber

    Faculty of Biochemistry

    6027
  • Combinatorial Approach to Inhibit Drug-Resistant Lung Cancer Harboring EGFR Mutations (No. T4-1944)

    Non-Small Cell Lung Cancer (NSCLC) is a very common type of cancer, and despite currently available therapies, is one of the deadliest due to the emergence of drug resistance, which results in tumor recurrence. ... Read more
    Extension Service Yosef Yarden

    Yosef Yarden

    Faculty of Biology

    6025
  • Modification for Improving the Efficiency of Genome Editing (No. T4-1930)

    CRISPR-Cas9 is a powerful tool for genome editing, widely used for basic research and the development of treatments for genetic diseases. However, its efficiency is currently limited. ... Read more
    Emeritus Yosef Shaul

    Yosef Shaul

    Faculty of Biochemistry

    6024
  • Methods of Identifying and Using Agents for Treating Diseases Associated with Intestinal Barrier Dysfunction (No. T4-1925)

    Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal (GI) tract, resulting in its damage and gut barrier dysfunction. ... Read more
    Extension Service Benjamin Geiger

    Benjamin Geiger

    Faculty of Biology

    5746
  • Anti-Lox antibody Like Compound for Duchenne Muscular Dystrophy (No. T4-1913)

    Duchenne muscular dystrophy (DMD) is a disease that affects approximately 1 in 3,500 boys with a life expectancy of ~26 years. ... Read more
    Full Professor Irit Sagi

    Irit Sagi

    Faculty of Biology

    6026
  • Person-specific Assessment of Probiotics Responsiveness (No. T4-1895)

    Probiotics are a widely consumed dietary supplement, however, their efficacy is controversial and not all individuals benefit from their use. Therefore, a predictive tool that distinguishes between probiotic-permissive and resistant individuals is needed. ... Read more
    Associate Professor Eran Elinav

    Eran Elinav

    Faculty of Biology

    5734

Pages

Subscribe to Pharmaceuticals